DelveInsight launched a new report on ‘Chemotherapy Induced Anemia – Epidemiology Forecast to 2030’
DelveInsight’s ‘Chemotherapy Induced Anemia – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Chemotherapy Induced Anemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the facts of the report
1. The incidence of anemia was greater in patients with advanced stages. 2. The risk of grade 2+ anemia was increased from 29% in stage I to 49% in stage IV. 3. The incidence of anaemia in cancer patients reported in literature varies significantly, ranging from 20% to 60% at the time of cancer diagnosis and reaching 60–90% during cancer treatments.
“According to the available literature, no gender bias as been observed in case of Chemotherapy-
Induced Anemia.” Anemia is the most common and persistent hematological abnormality in oncology patients. Chemotherapy-induced anemia (CIA) is a consequence of malignant invasion of normal tissue leading to blood loss, bone marrow infiltration with disruption of erythropoiesis, and functional iron deficiency as a consequence of inflammation. • Fatigue is the most common symptom of CIA, although vertigo, loss of appetite, poor concentration, and dyspnea are also frequently reported. Grade of anemia in combination with type of cancer and baseline cardiopulmonary function contribute to symptom severity.
The risk and severity of anemia during chemotherapy vary significantly depending on the type, schedule, and intensity of treatments, and whether the patient has received previous myelosuppressive chemotherapy or radiation therapy, as well as the patient’s underlying medical conditions. Current practices to treat CIA include packed red blood cell transfusions, erythropoietin stimulating agents (ESAs), and iron supplementation. In addition to novel screening mechanisms, various hormones and pharmacologic agents influence the prevention and management of CIA.
Novel treatment options, along with increasing awareness regarding CIA, are responsible for the growth of the therapeutic market.
Request for sample pages : https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-epidemiology-forecast
“According to DelveInsight, The increase in market size is a direct consequence of increasing incident population of cancer patients in the 7MM.”
Scope of the Report
KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
Reasons to buy
Key Assessments
Related Reports:
Chemotherapy Induced Anemia – Pipeline Insights, 2020
The Chemotherapy Induced Anemia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Chemotherapy Induced Anemia across the complete product development cycle, including all clinical and nonclinical stages.
Chemotherapy Induced Anemia- Market Insight, Epidemiology and Market Forecast -2030
The Chemotherapy Induced Anemia market report provides current treatment practices, emerging drugs, Chemotherapy Induced Anemia market share of the individual therapies, current and forecasted Chemotherapy Induced Anemia market Size from 2017 to 2030 segmented by seven major markets.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/